Wuxi Biologics Placement - Lesser Discount than Recent Deals but Still Looks Good
Wuxi Biologics Holdings is looking to raise up to US$513m by selling about 1.3% of Wuxi Biologics (2269 HK). This is the company's 16th placement...
Samsung Biologics (207940 KS): Near-Term Key Positive Catalysts
Upcoming participation in healthcare conference, Q4 result, and biosimilar launch in US are key catalysts to watch. Ongoing capex amid strong order...
Smartkarma Originals